BR0014583A - Receptor april (bcma) e seus usos - Google Patents

Receptor april (bcma) e seus usos

Info

Publication number
BR0014583A
BR0014583A BR0014583-1A BR0014583A BR0014583A BR 0014583 A BR0014583 A BR 0014583A BR 0014583 A BR0014583 A BR 0014583A BR 0014583 A BR0014583 A BR 0014583A
Authority
BR
Brazil
Prior art keywords
bcma
april
receptor
april receptor
antibodies
Prior art date
Application number
BR0014583-1A
Other languages
English (en)
Inventor
Pascal Schneider
Jeffrey Thompson
Teresa Cachero
Christiane Ambrose
Paul Rennert
Original Assignee
Biogen Inc
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27388102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Apotech R & D Sa filed Critical Biogen Inc
Publication of BR0014583A publication Critical patent/BR0014583A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "RECEPTOR APRIL (BCMA) E SEUS USOS". Um receptor na família de TNF é fornecido: APRIL-R. Moléculas quiméricas e anticorpos para APRIL-R e métodos de seu uso são também fornecidos.
BR0014583-1A 1999-10-06 2000-10-05 Receptor april (bcma) e seus usos BR0014583A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15793399P 1999-10-06 1999-10-06
US18180700P 2000-02-11 2000-02-11
US21568800P 2000-06-30 2000-06-30
PCT/US2000/027579 WO2001024811A1 (en) 1999-10-06 2000-10-05 April receptor (bcma) and uses thereof

Publications (1)

Publication Number Publication Date
BR0014583A true BR0014583A (pt) 2002-06-11

Family

ID=27388102

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014583-1A BR0014583A (pt) 1999-10-06 2000-10-05 Receptor april (bcma) e seus usos

Country Status (30)

Country Link
US (1) US7276241B2 (pt)
EP (3) EP2324844A3 (pt)
JP (2) JP4880155B2 (pt)
KR (1) KR100759295B1 (pt)
CN (1) CN1263507C (pt)
AT (1) ATE360434T1 (pt)
AU (1) AU776852B2 (pt)
BG (1) BG65473B1 (pt)
BR (1) BR0014583A (pt)
CA (1) CA2386463C (pt)
CZ (1) CZ297633B6 (pt)
DE (1) DE60034586T2 (pt)
DK (1) DK1223964T3 (pt)
EA (1) EA005601B1 (pt)
EE (1) EE05212B1 (pt)
GE (1) GEP20043375B (pt)
HK (1) HK1044710B (pt)
HU (1) HUP0203567A2 (pt)
IL (3) IL148839A0 (pt)
IS (1) IS6322A (pt)
MX (1) MXPA02003393A (pt)
NO (1) NO331683B1 (pt)
NZ (1) NZ517907A (pt)
PL (1) PL204010B1 (pt)
RS (1) RS51602B (pt)
SK (1) SK286331B6 (pt)
TR (1) TR200200912T2 (pt)
UA (1) UA74798C2 (pt)
WO (1) WO2001024811A1 (pt)
ZA (1) ZA200202578B (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6329503B1 (en) 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
NZ517782A (en) 1999-08-17 2004-01-30 Biogen Inc A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ES2609016T3 (es) * 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
WO2002094192A2 (en) * 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
AU2004251679C1 (en) * 2003-06-05 2009-05-28 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
KR20070001880A (ko) 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Ｂαｆｆ 길항제를 위한 치료 섭생법
CN101258166B (zh) 2004-04-22 2013-01-30 阿根西斯公司 与steap-1蛋白结合的抗体及其衍生的分子
CN1786016B (zh) * 2004-12-09 2010-12-29 中国人民解放军军事医学科学院基础医学研究所 一种人工构建的生物活性分子及其制备方法
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
NZ560285A (en) * 2005-01-28 2011-04-29 Biogen Idec Inc Use of baff to treat Th2-mediated conditions
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
JP2009507777A (ja) 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
US20120201823A1 (en) * 2009-10-14 2012-08-09 Schering Corporation April antagonists and methods of use
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
US9688767B2 (en) 2013-03-15 2017-06-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3430898A1 (en) 2013-11-19 2019-01-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
AU2016308567B2 (en) 2015-08-17 2022-10-27 Janssen Biotech, Inc. Anti-BCMA antibodies, bispecific antigen binding molecules that bind BCMA and CD3, and uses thereof
KR20190008171A (ko) * 2015-11-13 2019-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-bcma 폴리펩티드 및 단백질
KR20180091849A (ko) 2015-11-25 2018-08-16 비스테라, 인크. April에 대한 항체 분자 및 이의 용도
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
MX2019002967A (es) 2016-09-14 2019-07-04 Teneobio Inc Anticuerpos de union a cd3.
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
IL267485B2 (en) 2016-12-21 2024-01-01 Teneobio Inc Antibodies against BCMA containing only heavy chains and their uses
MA49289A (fr) 2017-04-03 2020-02-12 Hoffmann La Roche Anticorps se liant à steap-1
EP3642236A1 (en) 2017-06-20 2020-04-29 TeneoOne, Inc. Anti-bcma heavy chain-only antibodies
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20190352421A1 (en) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Methods of Treating Cancers and Enhancing Efficacy of T Cell Redirecting Therapeutics
MA52785A (fr) 2018-06-01 2021-04-14 Novartis Ag Molécules de liaison dirigées contre bcma et leurs utilisations
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN112585168B (zh) 2019-07-30 2022-04-15 上海翰森生物医药科技有限公司 抗bcma抗体、其抗原结合片段及其医药用途
EP4121172A1 (en) 2020-04-29 2023-01-25 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
JP2023524875A (ja) 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 多発性骨髄腫を治療するための方法
CN115996748A (zh) * 2020-05-29 2023-04-21 奇努克医疗公司 用APRIL结合抗体治疗IgA肾病的方法
CN116472049A (zh) 2020-06-30 2023-07-21 特尼奥生物股份有限公司 与bcma结合的多特异性抗体
IL305144A (en) 2021-02-16 2023-10-01 Janssen Pharmaceutica Nv Trispecific antibodies targeting BCMA, GPRC5D and CD3
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
WO2023019223A2 (en) 2021-08-11 2023-02-16 Akso Biopharmaceutical Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
PT897390E (pt) 1996-03-14 2004-03-31 Human Genome Sciences Inc Factor delta e epsilon de necrose tumoral humana
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
CA2292835A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP2001515711A (ja) * 1997-09-12 2001-09-25 バイオジェン インコーポレイテッド Ｋａｙ−新規の免疫系タンパク質
EA005411B1 (ru) * 1997-09-12 2005-02-24 Апотек Р Энд Д Са Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
ATE453712T1 (de) * 1999-01-07 2010-01-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
CA2363112A1 (en) 1999-02-23 2000-08-31 Craig A. Rosen Neutrokine-alpha and neutrokine-alpha splice variant
EP1157126A4 (en) * 1999-02-24 2005-03-02 Gen Hospital Corp PROCESS FOR CLONING INTERMEDIATE PRODUCTS FOR SIGNAL TRANSDUCTION
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
NZ517782A (en) 1999-08-17 2004-01-30 Biogen Inc A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
AU2001288260A1 (en) 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Also Published As

Publication number Publication date
NO20021594D0 (no) 2002-04-04
IL204401A (en) 2014-12-31
SK286331B6 (en) 2008-07-07
HK1044710B (zh) 2007-12-07
DE60034586T2 (de) 2008-02-28
US7276241B2 (en) 2007-10-02
BG65473B1 (bg) 2008-09-30
EP1223964A1 (en) 2002-07-24
EA200200427A1 (ru) 2002-12-26
UA74798C2 (uk) 2006-02-15
JP4880155B2 (ja) 2012-02-22
NZ517907A (en) 2004-01-30
SK4512002A3 (en) 2002-12-03
EE200200181A (et) 2003-06-16
IL148839A (en) 2015-01-29
AU776852B2 (en) 2004-09-23
KR100759295B1 (ko) 2007-09-18
AU7864500A (en) 2001-05-10
NO331683B1 (no) 2012-02-20
YU25302A (sh) 2005-06-10
CA2386463C (en) 2012-02-07
CA2386463A1 (en) 2001-04-12
GEP20043375B (en) 2004-11-25
DE60034586D1 (de) 2007-06-06
CZ297633B6 (cs) 2007-02-14
PL204010B1 (pl) 2009-12-31
EP1847273A1 (en) 2007-10-24
MXPA02003393A (es) 2004-08-19
RS51602B (sr) 2011-08-31
KR20020053066A (ko) 2002-07-04
EP2324844A2 (en) 2011-05-25
JP2011079863A (ja) 2011-04-21
DK1223964T3 (da) 2007-08-27
BG106670A (en) 2002-12-29
IS6322A (is) 2002-03-22
CN1399556A (zh) 2003-02-26
WO2001024811A1 (en) 2001-04-12
HUP0203567A2 (hu) 2003-02-28
EA005601B1 (ru) 2005-04-28
CZ20021169A3 (cs) 2002-09-11
EP1223964B1 (en) 2007-04-25
NO20021594L (no) 2002-06-05
TR200200912T2 (tr) 2002-07-22
IL148839A0 (en) 2002-09-12
ATE360434T1 (de) 2007-05-15
EP2324844A3 (en) 2013-12-11
HK1044710A1 (en) 2002-11-01
CN1263507C (zh) 2006-07-12
US20030082175A1 (en) 2003-05-01
ZA200202578B (en) 2003-07-02
JP2003510366A (ja) 2003-03-18
PL355102A1 (en) 2004-04-05
EE05212B1 (et) 2009-10-15

Similar Documents

Publication Publication Date Title
BR0014583A (pt) Receptor april (bcma) e seus usos
BR9909860A (pt) Polipeptìdeos cd19xcd3 especìficos e usos dos mesmos
SK500172015A3 (pt)
MA25872A1 (fr) Materiaux multi-usage sous forme de feuilles absorbant et resistant au dechirement
ATE114724T1 (de) Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente.
BR0110968A (pt) Antagonistas dos receptores de il-8
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
TR23792A (tr) Sulu sivi agartici terkibi
BR9707339A (pt) Composição de cuidado pessoal na forma de um líquido aquoso e uso da mesma
NO994516D0 (no) Brönnhodeelement for opptak av faste bestanddeler i produksjonsfluid
BR9815335A (pt) Uso de antagonistas de receptor de endotelina.
NO913774L (no) Cykloheksylfenylpyrimidiner, fremgangsmaate for fremstilling og anvendelse derav i vaeskekrystallinske blandinger
DE69434489D1 (de) Flüssige mischung aus sorbitol, mannitol und glyzerin und sie enthaltende zusammensetzung
NO20001894D0 (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
DE69009824T2 (de) Pyrimidin-Derivat und dieses enthaltende Flüssigkristall-Zusammensetzung.
BR0010985A (pt) Antagonistas de receptor de il-8
ITFI990040A0 (it) Uso della metformina per la preparazione di composizioni farmaceutiche per determinare l'aumento della concentrazione plasmatica di glucagon
EE200900055A (et) TNF/NFG retseptoriperekonna retseptorite ja muude valkude talitluse modulaatorid, nende valmistamine ja kasutamine ning farmatseutiline kompositsioon
ITPN20030081A1 (it) Bicchiere contenente bevande sigillato e pronto all'uso.
ITMC920010A1 (it) Doppio uso di molla in cerchio-quadrato

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: APOTECH RANDD S.A. (CH) , BIOGEN IDEC MA, INC. (US

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: APOTECH RANDD S.A. (CH) , BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 10 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.